CD4/CD8 Ratio Outcome According to the Class of the Third Active Drug in Antiretroviral Therapy Regimens: Results From the Quebec Human Immunodeficiency Virus Cohort Study
Clinical Infectious Diseases · 2023
DOI: 10.1093/cid/ciad056 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Mohamed N'dongo Sangaré und 10 weiteren Autor:innen. Beteiligte Einrichtung: Université du Québec en Abitibi-Témiscamingue, Rouyn-Noranda, Canada. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Quebec HIV Cohort, Fonds de la Recherche du Québec en Santé, (FRQS).
Abstract (Originalsprache)
Background
The impact of different therapeutic classes of drugs in antiretroviral therapy (ART) regimens on the CD4/CD8 ratio is not well documented in people treated for HIV. The objective of this study was to analyze the long-term effect of exposure to integrase strand transfer inhibitor (INSTI) on CD4/CD8 ratio compared with nonnucleoside reverse transcriptase inhibitor (NNRTI) or protease inhibitor (PI) among ART-treated persons with HIV (PWH).
Methods
Data from the Quebec HIV Cohort collected from 31 August 2017 were used. Our analysis included all patients in the cohort who received a first or subsequent ART regimen composed of 2 nucleoside reverse transcriptase inhibitors (NRTIs) and a third active drug of a different class (NNRTI, PI, or INSTI) for at least 16 weeks. Marginal structural Cox models were constructed to estimate the effect of different therapeutic classes on the CD4/CD8 ratio outcome.
Results
Among the 3907 eligible patients, 972 (24.9%), 1996 (51.1%), and 939 (24.0%) were exposed to an ART regimen whose third active agent was an NNRTI, PI, or INSTI, respectively. The total follow-up time was 13 640.24 person-years. The weighted hazard ratio for the association between the third active class and CD4/CD8 ratio ≥1 was .56 (95% confidence interval [CI]: .48–.65) for patients exposed to NNRTI + 2 NRTIs and .41 (95% CI: .35–.47) for those exposed to PI + 2 NRTIs, compared with those exposed INSTI + 2 NRTIs.
Conclusions
For people treated for HIV, INSTI-based ART appears to be associated with a higher CD4/CD8 ratio than NNRTI and PI-based ART.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université du Québec en Abitibi-Témiscamingue, Rouyn-Noranda, Canada.
- Clinique de Médecine Urbaine du Quartier Latin, Montreal, Canada.
- Faculty of Medicine, Université de Montréal, Montreal, Canada.
- Centre Hospitalier de l'Université de Montréal, Montreal, Canada.
- Chronic Viral Illness Service, McGill University Health Centre, Montreal, Canada.
- Department of Family Medicine, McGill University, Montreal, Canada.
Förderung
- Quebec HIV Cohort
- Fonds de la Recherche du Québec en Santé
- (FRQS)
- Réseau SIDA-MI
Zitieren
APA
Sangaré, M. N., Baril, J. G., de Pokomandy, A., Klein, M., Thomas, R., Tremblay, C., Pexos, C., Durand, M., Chawla, S., Laporte, L., & Trottier, H. (2023). CD4/CD8 Ratio Outcome According to the Class of the Third Active Drug in Antiretroviral Therapy Regimens: Results From the Quebec Human Immunodeficiency Virus Cohort Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad056
Vancouver
Sangaré MN, Baril JG, de Pokomandy A, Klein M, Thomas R, Tremblay C, et al. CD4/CD8 Ratio Outcome According to the Class of the Third Active Drug in Antiretroviral Therapy Regimens: Results From the Quebec Human Immunodeficiency Virus Cohort Study. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad056
BibTeX
@article{Sangar2023,
author = {Sangaré, Mohamed N'dongo and Baril, Jean-Guy and de Pokomandy, Alexandra and Klein, Marina and Thomas, Réjean and Tremblay, Cécile and Pexos, Costa and Durand, Madeleine and Chawla, Seerat and Laporte, Louise and Trottier, Helen},
title = {CD4/CD8 Ratio Outcome According to the Class of the Third Active Drug in Antiretroviral Therapy Regimens: Results From the Quebec Human Immunodeficiency Virus Cohort Study},
journal = {Clinical Infectious Diseases},
year = {2023},
doi = {10.1093/cid/ciad056}
}
EUVIMED